Clinical presentation and prognosis in MOG-antibody disease: a UK study
Jurynczyk M. et al, (2017), Brain, 140, 3128 - 3138
Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis
Jurynczyk M. et al, (2017), Brain, 140, 617 - 627
Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease
Juryńczyk M. et al, (2017), Journal of Neurology, Neurosurgery & Psychiatry, 88, 132 - 136
Chronic neuropathic pain severity is determined by lesion level in aquaporin 4-antibody-positive myelitis
Tackley G. et al, (2017), Journal of Neurology, Neurosurgery & Psychiatry, 88, 165 - 169
Isolated new onset ‘atypical’ optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up
Piccolo L. et al, (2016), Journal of Neurology, 263, 370 - 379
Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes
Juryńczyk M. et al, (2016), Journal of Neurology, 263, 140 - 149
MOG cell-based assay detects non-MS patients with inflammatory neurologic disease
Waters P. et al, (2015), Neurology - Neuroimmunology Neuroinflammation, 2, e89 - e89
Overlapping CNS inflammatory diseases: differentiating features of NMO and MS
Juryńczyk M. et al, (2015), Journal of Neurology, Neurosurgery & Psychiatry, 86, 20 - 25